Takeda Pharmaceutical Company Limited TKPHF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 29.83B | 29.91B | 29.92B | 29.85B | 29.62B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.83B | 29.91B | 29.92B | 29.85B | 29.62B |
| Cost of Revenue | 10.51B | 10.62B | 10.73B | 10.29B | 10.42B |
| Gross Profit | 19.32B | 19.29B | 19.18B | 19.56B | 19.20B |
| SG&A Expenses | 7.20B | 7.21B | 7.19B | 7.27B | 7.21B |
| Depreciation & Amortization | 2.72B | 3.02B | 3.26B | 3.49B | 3.49B |
| Other Operating Expenses | 224.47M | 655.24M | 487.22M | 337.94M | 821.31M |
| Total Operating Expenses | 25.12B | 25.99B | 26.09B | 26.03B | 26.56B |
| Operating Income | 4.70B | 3.92B | 3.83B | 3.82B | 3.06B |
| Income Before Tax | -29.36M | -818.69M | -797.11M | 1.40B | 703.04M |
| Income Tax Expenses | -275.36M | 224.59M | 96.58M | 620.97M | 442.33M |
| Earnings from Continuing Operations | 246.00 | -1.04K | -893.69 | 777.52 | 260.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.56M | -1.87M | -1.74M | -1.72M | -1.41M |
| Net Income | 244.44M | -1.05B | -895.43M | 775.80M | 259.30M |
| EBIT | 4.70B | 3.92B | 3.83B | 3.82B | 3.06B |
| EBITDA | 8.45B | 7.88B | 8.03B | 8.22B | 7.45B |
| EPS Basic | 0.15 | -0.66 | -0.56 | 0.50 | 0.17 |
| Normalized Basic EPS | 1.47 | 1.18 | 1.15 | 1.26 | 0.85 |
| EPS Diluted | 0.12 | -0.68 | -0.58 | 0.48 | 0.16 |
| Normalized Diluted EPS | 1.45 | 1.17 | 1.14 | 1.25 | 0.84 |
| Average Basic Shares Outstanding | 6.33B | 6.32B | 6.30B | 6.30B | 6.31B |
| Average Diluted Shares Outstanding | 6.41B | 6.37B | 6.35B | 6.35B | 6.33B |
| Dividend Per Share | 1.28 | 1.32 | 1.32 | 1.32 | 1.32 |
| Payout Ratio | 823.92% | -193.75% | -233.25% | 270.24% | 803.40% |